BACKGROUND: Palifermin is a recombinant human keratinocyte growth factor that is used to reduce the duration and severity of oral mucositis in patients undergoing hematopoietic stem cell transplantation after myelotoxic therapy. Cutaneous adverse reactions associated with keratinocyte growth factor are reported to be rash, pruritus, and erythema. OBSERVATIONS: After receiving palifermin following autologous hematopoietic stem cell transplantation and treatment with melphalan, a patient developed erythema and lichenoid papules that were distributed primarily in intertriginous areas. A biopsy specimen of the papules showed a striking resemblance to verrucae, but in situ hybridization studies were negative for human papillomavirus. Immunohistochemical staining with antibodies to Ki-67 and cytokeratin 5/6 showed increased keratinocyte proliferation in lesional skin. CONCLUSIONS: After treatment with palifermin, a papular eruption clinically resembling lichen planus or plane warts, with histologic features of verruca plana, and intertriginous erythema may occur. In this case, neither eruption required treatment, and spontaneous resolution was observed over days to weeks. Histopathologic staining patterns of Ki-67 and cytokeratin 5/6 may be useful in identifying adverse reactions to palifermin therapy.
BACKGROUND: Palifermin is a recombinant humankeratinocyte growth factor that is used to reduce the duration and severity of oral mucositis in patients undergoing hematopoietic stem cell transplantation after myelotoxic therapy. Cutaneous adverse reactions associated with keratinocyte growth factor are reported to be rash, pruritus, and erythema. OBSERVATIONS: After receiving palifermin following autologous hematopoietic stem cell transplantation and treatment with melphalan, a patient developed erythema and lichenoid papules that were distributed primarily in intertriginous areas. A biopsy specimen of the papules showed a striking resemblance to verrucae, but in situ hybridization studies were negative for human papillomavirus. Immunohistochemical staining with antibodies to Ki-67 and cytokeratin 5/6 showed increased keratinocyte proliferation in lesional skin. CONCLUSIONS: After treatment with palifermin, a papular eruption clinically resembling lichen planus or plane warts, with histologic features of verruca plana, and intertriginous erythema may occur. In this case, neither eruption required treatment, and spontaneous resolution was observed over days to weeks. Histopathologic staining patterns of Ki-67 and cytokeratin 5/6 may be useful in identifying adverse reactions to palifermin therapy.
Authors: Parnian Zia-Amirhosseini; Margaret Salfi; Philip Leese; Wayne Yates; Dimitry M Danilenko; Brian Ring; Alessandra Cesano; John T Sullivan Journal: Clin Pharmacol Ther Date: 2006-06 Impact factor: 6.875
Authors: Ricardo Spielberger; Patrick Stiff; William Bensinger; Teresa Gentile; Daniel Weisdorf; Tarun Kewalramani; Thomas Shea; Saul Yanovich; Keith Hansen; Stephen Noga; John McCarty; C Frederick LeMaistre; Eric C Sung; Bruce R Blazar; Dieter Elhardt; Mon-Gy Chen; Christos Emmanouilides Journal: N Engl J Med Date: 2004-12-16 Impact factor: 91.245
Authors: C L Farrell; J V Bready; K L Rex; J N Chen; C R DiPalma; K L Whitcomb; S Yin; D C Hill; B Wiemann; C O Starnes; A M Havill; Z N Lu; S L Aukerman; G F Pierce; A Thomason; C S Potten; T R Ulich; D L Lacey Journal: Cancer Res Date: 1998-03-01 Impact factor: 12.701
Authors: C K Jiang; T Magnaldo; M Ohtsuki; I M Freedberg; F Bernerd; M Blumenberg Journal: Proc Natl Acad Sci U S A Date: 1993-07-15 Impact factor: 11.205
Authors: A Grzegorczyk-Jaźwińska; I Kozak; E Karakulska-Prystupiuk; M Rokicka; E Ganowicz; J Dwilewicz-Trojaczek; R Górska Journal: Adv Med Sci Date: 2006 Impact factor: 3.287
Authors: Skylar Klager; Mario E Lacouture; Margaret Hannum; Sean M Devlin; Molly Maloy; Melissa Pulitzer; Ann A Jakubowski; Alina Markova Journal: Biol Blood Marrow Transplant Date: 2019-07-12 Impact factor: 5.742